TNDM
Tandem Diabetes Care, Inc. NASDAQ Listed Nov 14, 2013$18.47
Mkt Cap $1.3B
52w Low $9.98
43.2% of range
52w High $29.65
50d MA $21.37
200d MA $18.08
P/E (TTM)
-6.4x
EV/EBITDA
-10.5x
P/B
8.4x
Debt/Equity
2.9x
ROE
-0.4%
P/FCF
-49.8x
RSI (14)
—
ATR (14)
—
Beta
1.74
50d MA
$21.37
200d MA
$18.08
Avg Volume
2.1M
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
11075 Roselle Street · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.46 | -0.30 | +34.8% | 18.47 | +8.3% | -16.2% | — | — | — | — | — |
| Feb 19, 2026 | AMC | -0.05 | -0.01 | +80.0% | 18.52 | +22.8% | +32.7% | +15.0% | -4.8% | -3.3% | -0.8% | — |
| Nov 6, 2025 | AMC | -0.31 | -0.31 | +0.0% | 13.33 | +20.0% | +22.0% | +0.7% | +7.0% | +3.1% | -2.9% | — |
| Aug 6, 2025 | AMC | -0.40 | -0.48 | -20.0% | 14.39 | -27.0% | -19.9% | -2.5% | -9.9% | +9.8% | +0.2% | — |
| Apr 30, 2025 | AMC | -0.60 | -0.67 | -11.7% | 16.85 | +10.7% | +18.6% | +7.5% | -0.9% | +0.1% | +4.4% | — |
| Feb 26, 2025 | AMC | -0.25 | -0.44 | -76.0% | 33.59 | -28.0% | -35.2% | +1.8% | -6.1% | -6.2% | -1.9% | — |
| Nov 6, 2024 | AMC | -0.43 | -0.36 | +16.3% | 34.24 | -4.8% | -2.7% | -8.2% | +2.5% | -0.9% | -4.6% | — |
| Aug 1, 2024 | AMC | -0.54 | -0.47 | +13.0% | 35.21 | +17.2% | +18.3% | -2.1% | +6.4% | -14.6% | -0.4% | — |
| May 2, 2024 | AMC | -0.80 | -0.63 | +21.2% | 36.56 | +17.4% | +22.3% | -2.7% | +1.1% | -4.2% | +4.5% | — |
| Feb 21, 2024 | AMC | -0.23 | -0.27 | -17.4% | 22.55 | +8.6% | +10.9% | +16.5% | -0.9% | -5.3% | -2.8% | — |
| Nov 1, 2023 | AMC | -0.35 | -0.38 | -8.6% | 17.75 | -11.3% | -14.4% | +3.6% | -2.8% | +6.2% | -4.6% | — |
| Aug 3, 2023 | AMC | -0.54 | -0.30 | +44.4% | 31.99 | -6.6% | +4.4% | -9.8% | -6.6% | +1.7% | +2.4% | — |
| May 3, 2023 | AMC | -0.56 | -0.63 | -12.5% | 39.95 | -11.9% | -6.1% | -6.5% | -4.6% | -2.2% | +1.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | TD Cowen | Maintains | Buy → Buy | — | $20.61 | $20.88 | +1.3% | +3.1% | -5.7% | +3.7% | -0.5% | -1.5% |
| Apr 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.35 | $19.34 | -0.1% | +1.7% | -2.5% | +4.8% | +5.0% | -2.1% |
| Mar 19 | Truist | Upgrade | Hold → Buy | — | $23.85 | $25.04 | +5.0% | +3.3% | +0.8% | +1.1% | -2.3% | -1.0% |
| Mar 17 | Piper Sandler | Upgrade | Neutral → Overweight | — | $21.91 | $23.16 | +5.7% | +9.1% | -0.3% | +3.3% | +0.8% | +1.1% |
| Mar 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.30 | $24.88 | -1.7% | -0.3% | -5.9% | -1.4% | -3.3% | -6.6% |
| Feb 23 | Lake Street | Upgrade | Hold → Buy | — | $24.57 | $25.59 | +4.2% | +15.0% | -4.8% | -3.3% | -0.8% | -1.9% |
| Feb 23 | Truist | Maintains | Hold → Hold | — | $24.57 | $25.59 | +4.2% | +15.0% | -4.8% | -3.3% | -0.8% | -1.9% |
| Feb 20 | BofA Securities | Upgrade | Underperform → Neutral | — | $18.52 | $22.75 | +22.8% | +32.7% | +15.0% | -4.8% | -3.3% | -0.8% |
| Feb 20 | Piper Sandler | Maintains | Neutral → Neutral | — | $18.52 | $22.75 | +22.8% | +32.7% | +15.0% | -4.8% | -3.3% | -0.8% |
| Feb 20 | UBS | Maintains | Neutral → Neutral | — | $18.52 | $22.75 | +22.8% | +32.7% | +15.0% | -4.8% | -3.3% | -0.8% |
| Feb 20 | Stifel | Maintains | Hold → Hold | — | $18.52 | $22.75 | +22.8% | +32.7% | +15.0% | -4.8% | -3.3% | -0.8% |
| Feb 20 | Mizuho | Maintains | Neutral → Neutral | — | $18.52 | $22.75 | +22.8% | +32.7% | +15.0% | -4.8% | -3.3% | -0.8% |
| Feb 4 | Stifel | Maintains | Hold → Hold | — | $19.44 | $19.44 | +0.0% | -2.3% | -0.3% | +1.2% | -1.5% | +3.4% |
| Jan 9 | Bernstein | Maintains | Market Perform → Market Perform | — | $22.50 | $23.03 | +2.4% | -3.6% | -1.6% | -2.1% | -0.1% | +1.0% |
| Dec 18 | Truist | Maintains | Hold → Hold | — | $22.42 | $22.44 | +0.1% | -2.8% | +1.2% | +5.4% | -2.8% | -0.6% |
| Dec 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $22.60 | $22.67 | +0.3% | -0.8% | -2.8% | +1.2% | +5.4% | -2.8% |
| Dec 17 | Mizuho | Maintains | Neutral → Neutral | — | $22.60 | $22.67 | +0.3% | -0.8% | -2.8% | +1.2% | +5.4% | -2.8% |
| Dec 16 | Baird | Upgrade | Neutral → Outperform | — | $22.11 | $24.46 | +10.6% | +2.2% | -0.8% | -2.8% | +1.2% | +5.4% |
| Dec 11 | Citigroup | Maintains | Neutral → Neutral | — | $21.45 | $20.78 | -3.1% | -2.2% | +2.0% | +3.4% | +2.2% | -0.8% |
| Dec 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $20.51 | $20.73 | +1.1% | -4.3% | +1.6% | +3.9% | +1.0% | -0.9% |
| Nov 10 | Truist | Maintains | Hold → Hold | — | $16.26 | $16.51 | +1.5% | +0.7% | +7.0% | +3.1% | -2.9% | +6.2% |
| Nov 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $16.26 | $16.51 | +1.5% | +0.7% | +7.0% | +3.1% | -2.9% | +6.2% |
| Nov 10 | Barclays | Maintains | Overweight → Overweight | — | $16.26 | $16.51 | +1.5% | +0.7% | +7.0% | +3.1% | -2.9% | +6.2% |
| Nov 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $13.33 | $16.00 | +20.0% | +22.0% | +0.7% | +7.0% | +3.1% | -2.9% |
| Oct 15 | Truist | Maintains | Hold → Hold | — | $14.38 | $14.52 | +1.0% | +2.6% | +3.7% | -3.3% | +5.1% | -1.0% |
| Oct 7 | Citigroup | Maintains | Neutral → Neutral | — | $15.01 | $15.14 | +0.9% | -3.3% | +5.6% | -3.4% | -5.5% | -0.9% |
| Sep 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $12.00 | $12.08 | +0.7% | -1.8% | +3.0% | +2.2% | +5.6% | +12.2% |
| Sep 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.58 | $12.59 | +0.1% | -0.6% | +0.5% | -1.5% | +3.4% | -4.1% |
| Aug 21 | Citigroup | Maintains | Neutral → Neutral | — | $10.68 | $10.56 | -1.1% | +3.5% | +8.0% | +1.5% | +1.1% | +0.1% |
| Aug 12 | Citigroup | Upgrade | Sell → Neutral | — | $10.12 | $11.07 | +9.4% | +9.8% | +0.2% | -4.2% | +1.5% | +0.2% |
| Aug 11 | Lake Street | Downgrade | Buy → Hold | — | $11.23 | $11.11 | -1.1% | -9.9% | +9.8% | +0.2% | -4.2% | +1.5% |
| Aug 8 | Barclays | Maintains | Overweight → Overweight | — | $11.52 | $11.65 | +1.1% | -2.5% | -9.9% | +9.8% | +0.2% | -4.2% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $14.39 | $10.50 | -27.0% | -19.9% | -2.5% | -9.9% | +9.8% | +0.2% |
| Aug 7 | Piper Sandler | Downgrade | Overweight → Neutral | — | $14.39 | $10.50 | -27.0% | -19.9% | -2.5% | -9.9% | +9.8% | +0.2% |
| Aug 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $14.39 | $10.50 | -27.0% | -19.9% | -2.5% | -9.9% | +9.8% | +0.2% |
| Aug 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $14.39 | $10.50 | -27.0% | -19.9% | -2.5% | -9.9% | +9.8% | +0.2% |
| Aug 7 | UBS | Maintains | Neutral → Neutral | — | $14.39 | $10.50 | -27.0% | -19.9% | -2.5% | -9.9% | +9.8% | +0.2% |
| Jul 9 | Citigroup | Downgrade | Neutral → Sell | — | $16.62 | $15.34 | -7.7% | -4.6% | +2.0% | -3.6% | +1.0% | -3.5% |
| May 22 | Citigroup | Maintains | Neutral → Neutral | — | $21.65 | $21.58 | -0.3% | -4.7% | +0.4% | +3.7% | -1.5% | +0.6% |
| May 1 | Stifel | Maintains | Buy → Buy | — | $16.85 | $18.66 | +10.7% | +18.6% | +7.5% | -0.9% | +0.1% | +4.4% |
| May 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $16.85 | $18.66 | +10.7% | +18.6% | +7.5% | -0.9% | +0.1% | +4.4% |
| May 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $16.85 | $18.66 | +10.7% | +18.6% | +7.5% | -0.9% | +0.1% | +4.4% |
| May 1 | Baird | Maintains | Neutral → Neutral | — | $16.85 | $18.66 | +10.7% | +18.6% | +7.5% | -0.9% | +0.1% | +4.4% |
| May 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.85 | $18.66 | +10.7% | +18.6% | +7.5% | -0.9% | +0.1% | +4.4% |
| Mar 5 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $19.49 | $19.18 | -1.6% | -1.9% | -2.0% | -4.1% | +1.1% | -1.5% |
| Mar 4 | Citigroup | Downgrade | Buy → Neutral | — | $20.78 | $20.00 | -3.8% | -6.2% | -1.9% | -2.0% | -4.1% | +1.1% |
| Mar 3 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $22.14 | $21.83 | -1.4% | -6.1% | -6.2% | -1.9% | -2.0% | -4.1% |
| Mar 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $22.14 | $21.83 | -1.4% | -6.1% | -6.2% | -1.9% | -2.0% | -4.1% |
| Feb 28 | Barclays | Maintains | Overweight → Overweight | — | $21.75 | $21.68 | -0.3% | +1.8% | -6.1% | -6.2% | -1.9% | -2.0% |
| Feb 27 | RBC Capital | Maintains | Outperform → Outperform | — | $33.59 | $24.18 | -28.0% | -35.2% | +1.8% | -6.1% | -6.2% | -1.9% |
No insider trades available.
8-K · 1.01
!! High
Tandem Diabetes Care, Inc. -- 8-K 1.01: Material Agreement
Tandem Diabetes Care issued convertible notes on February 27, 2026, providing capital for operations and potential acquisitions while giving investors conversion rights into company stock.
Feb 27
8-K
Tandem Diabetes Care, Inc. -- 8-K Filing
Tandem Diabetes Care reported Q4 and full-year 2025 financial results, providing 2026 guidance as a global insulin delivery company navigates ongoing market dynamics.
Feb 19
Data updated apr 27, 2026 5:10am
· Source: massive.com